Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Corrigendum: Continuous Release of Tumor-Derived Factors Improves the Modeling of Cachexia in Muscle Cell Culture.

Jackman RW, Floro J, Yoshimine R, Zitin B, Eiampikul M, El-Jack K, Seto DN, Kandarian SC.

Front Physiol. 2019 Apr 9;10:394. doi: 10.3389/fphys.2019.00394. eCollection 2019.

2.

Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice.

Kandarian SC, Nosacka RL, Delitto AE, Judge AR, Judge SM, Ganey JD, Moreira JD, Jackman RW.

J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1109-1120. doi: 10.1002/jcsm.12346. Epub 2018 Sep 30.

3.

Continuous Release of Tumor-Derived Factors Improves the Modeling of Cachexia in Muscle Cell Culture.

Jackman RW, Floro J, Yoshimine R, Zitin B, Eiampikul M, El-Jack K, Seto DN, Kandarian SC.

Front Physiol. 2017 Sep 25;8:738. doi: 10.3389/fphys.2017.00738. eCollection 2017. Erratum in: Front Physiol. 2019 Apr 09;10:394.

4.

A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia.

Seto DN, Kandarian SC, Jackman RW.

J Biol Chem. 2015 Aug 7;290(32):19976-86. doi: 10.1074/jbc.M115.638411. Epub 2015 Jun 19.

5.

NF-κB but not FoxO sites in the MuRF1 promoter are required for transcriptional activation in disuse muscle atrophy.

Wu CL, Cornwell EW, Jackman RW, Kandarian SC.

Am J Physiol Cell Physiol. 2014 Apr 15;306(8):C762-7. doi: 10.1152/ajpcell.00361.2013. Epub 2014 Feb 19.

6.

C26 cancer-induced muscle wasting is IKKβ-dependent and NF-kappaB-independent.

Cornwell EW, Mirbod A, Wu CL, Kandarian SC, Jackman RW.

PLoS One. 2014 Jan 29;9(1):e87776. doi: 10.1371/journal.pone.0087776. eCollection 2014.

7.

The ChIP-seq-defined networks of Bcl-3 gene binding support its required role in skeletal muscle atrophy.

Jackman RW, Wu CL, Kandarian SC.

PLoS One. 2012;7(12):e51478. doi: 10.1371/journal.pone.0051478. Epub 2012 Dec 10.

8.

Nuclear factor-κB signalling and transcriptional regulation in skeletal muscle atrophy.

Jackman RW, Cornwell EW, Wu CL, Kandarian SC.

Exp Physiol. 2013 Jan;98(1):19-24. doi: 10.1113/expphysiol.2011.063321. Epub 2012 Jul 30. Review.

9.

Rel A/p65 is required for cytokine-induced myotube atrophy.

Yamaki T, Wu CL, Gustin M, Lim J, Jackman RW, Kandarian SC.

Am J Physiol Cell Physiol. 2012 Jul 15;303(2):C135-42. doi: 10.1152/ajpcell.00111.2012. Epub 2012 May 16.

10.

Distinct roles of trauma and transfusion in induction of immune modulation after injury.

Jackman RP, Utter GH, Muench MO, Heitman JW, Munz MM, Jackman RW, Biswas HH, Rivers RM, Tobler LH, Busch MP, Norris PJ.

Transfusion. 2012 Dec;52(12):2533-50. doi: 10.1111/j.1537-2995.2012.03618.x. Epub 2012 Mar 27.

11.

Identification of genes that elicit disuse muscle atrophy via the transcription factors p50 and Bcl-3.

Wu CL, Kandarian SC, Jackman RW.

PLoS One. 2011 Jan 13;6(1):e16171. doi: 10.1371/journal.pone.0016171.

12.

Microtubule-mediated NF-kappaB activation in the TNF-alpha signaling pathway.

Jackman RW, Rhoads MG, Cornwell E, Kandarian SC.

Exp Cell Res. 2009 Nov 15;315(19):3242-9. doi: 10.1016/j.yexcr.2009.08.020. Epub 2009 Sep 2.

13.

The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy.

Van Gammeren D, Damrauer JS, Jackman RW, Kandarian SC.

FASEB J. 2009 Feb;23(2):362-70. doi: 10.1096/fj.08-114249. Epub 2008 Sep 30.

14.
15.

Role for IkappaBalpha, but not c-Rel, in skeletal muscle atrophy.

Judge AR, Koncarevic A, Hunter RB, Liou HC, Jackman RW, Kandarian SC.

Am J Physiol Cell Physiol. 2007 Jan;292(1):C372-82. Epub 2006 Aug 23.

16.

Intracellular signaling during skeletal muscle atrophy.

Kandarian SC, Jackman RW.

Muscle Nerve. 2006 Feb;33(2):155-65. Review.

PMID:
16228971
17.

Transcriptional profile of a myotube starvation model of atrophy.

Stevenson EJ, Koncarevic A, Giresi PG, Jackman RW, Kandarian SC.

J Appl Physiol (1985). 2005 Apr;98(4):1396-406. Epub 2004 Dec 17.

18.

The molecular basis of skeletal muscle atrophy.

Jackman RW, Kandarian SC.

Am J Physiol Cell Physiol. 2004 Oct;287(4):C834-43. Review.

19.

Upstream stimulatory factors stimulate transcription through E-box motifs in the PF4 gene in megakaryocytes.

Okada Y, Matsuura E, Tozuka Z, Nagai R, Watanabe A, Matsumoto K, Yasui K, Jackman RW, Nakano T, Doi T.

Blood. 2004 Oct 1;104(7):2027-34. Epub 2004 Jun 8.

PMID:
15187018
20.

Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis.

Hekking LH, Harvey VS, Havenith CE, van den Born J, Beelen RH, Jackman RW, Nagy JA.

Perit Dial Int. 2003 Jul-Aug;23(4):323-30.

PMID:
12968839
21.

Modulation of transgene expression in mesothelial cells by activation of an inducible promoter.

Hoff CM, Cusick JL, Masse EM, Jackman RW, Nagy JA, Shockley TR.

Nephrol Dial Transplant. 1998 Jun;13(6):1420-9.

PMID:
9641171
22.

Enhancement of the functional repertoire of the rat parietal peritoneal mesothelium in vivo: directed expression of the anticoagulant and antiinflammatory molecule thrombomodulin.

Jackman RW, Stapleton TD, Masse EM, Harvey VS, Meyers MS, Shockley TR, Nagy JA.

Hum Gene Ther. 1998 May 1;9(7):1069-81.

PMID:
9607418
23.

Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.

Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP.

J Invest Dermatol. 1997 Mar;108(3):263-8.

24.

Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia.

Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, Brown LF.

J Natl Cancer Inst. 1995 Aug 16;87(16):1237-45.

PMID:
7563170
25.

Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface.

Nagy JA, Shockley TR, Masse EM, Harvey VS, Hoff CM, Jackman RW.

Gene Ther. 1995 Aug;2(6):402-10.

PMID:
7584115
26.

Mesothelial cell-mediated gene therapy: feasibility of an ex vivo strategy.

Nagy JA, Shockley TR, Masse EM, Harvey VS, Jackman RW.

Gene Ther. 1995 Aug;2(6):393-401.

PMID:
7584114
27.

Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme.

Brown LF, Harrist TJ, Yeo KT, Ståhle-Bäckdahl M, Jackman RW, Berse B, Tognazzi K, Dvorak HF, Detmar M.

J Invest Dermatol. 1995 May;104(5):744-9.

28.

Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions.

Brown LF, Olbricht SM, Berse B, Jackman RW, Matsueda G, Tognazzi KA, Manseau EJ, Dvorak HF, Van de Water L.

J Immunol. 1995 Mar 15;154(6):2801-7.

PMID:
7876550
29.

Platelet attachment stimulates endothelial cell regeneration after arterial injury.

Kent KC, Wroblewski L, Jackman RW, Skillman JJ.

Surgery. 1995 Mar;117(3):276-81.

PMID:
7878533
30.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ.

Hum Pathol. 1995 Jan;26(1):86-91.

PMID:
7821921
31.
32.

Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.

Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF.

J Exp Med. 1994 Sep 1;180(3):1141-6.

33.

Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue.

Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF.

J Exp Med. 1994 Jul 1;180(1):341-6.

34.

Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas.

Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR.

Am J Pathol. 1993 Nov;143(5):1255-62.

35.

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF.

Cancer Res. 1993 Oct 1;53(19):4727-35.

PMID:
8402650
36.

Vascular permeability factor (VPF, VEGF) in tumor biology.

Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF.

Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24. Review.

PMID:
8281615
37.

Transcriptional regulation of the thrombomodulin gene.

Yu K, Morioka H, Fritze LM, Beeler DL, Jackman RW, Rosenberg RD.

J Biol Chem. 1992 Nov 15;267(32):23237-47.

39.

Thrombomodulin in the central nervous system.

Boffa MC, Jackman RW, Peyri N, Boffa JF, George B.

Nouv Rev Fr Hematol. 1991;33(6):423-9.

PMID:
1667949
40.
41.
42.

Restoration of LDL receptor activity in mutant cells by intercellular junctional communication.

Hobbie L, Kingsley DM, Kozarsky KF, Jackman RW, Krieger M.

Science. 1987 Jan 2;235(4784):69-73.

PMID:
3798096
43.

Characterization of a thrombomodulin cDNA reveals structural similarity to the low density lipoprotein receptor.

Jackman RW, Beeler DL, VanDeWater L, Rosenberg RD.

Proc Natl Acad Sci U S A. 1986 Dec;83(23):8834-8.

44.

Anticoagulantly active heparin-like molecules from mast cell-deficient mice.

Marcum JA, McKenney JB, Galli SJ, Jackman RW, Rosenberg RD.

Am J Physiol. 1986 May;250(5 Pt 2):H879-88.

PMID:
3706560
45.

Persistence of axial orientation cues in regenerating intima of cultured aortic explants.

Jackman RW.

Nature. 1982 Mar 4;296(5852):80-3. No abstract available.

PMID:
7063010
46.

An interpretation of the relation between objective and subjective social status.

Jackman MR, Jackman RW.

Am Sociol Rev. 1973 Oct;38(5):569-82. No abstract available.

PMID:
4745630

Supplemental Content

Loading ...
Support Center